{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:44:33Z","timestamp":1791225873828,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CHAIN","award":["223131"],"award-info":[{"award-number":["223131"]}]},{"name":"Italian Ministry of Health","award":["Project n. 2"],"award-info":[{"award-number":["Project n. 2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virus Genes"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11262-019-01649-z","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T08:51:55Z","timestamp":1550825515000},"page":"290-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice"],"prefix":"10.1007","volume":"55","author":[{"given":"Claudia","family":"Alteri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Scutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Maria","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Cerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cristaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Vicenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Svicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"1649_CR1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1086\/587660","volume":"46","author":"L Waters","year":"2008","unstructured":"Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G (2008) The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46:1617\u20131623","journal-title":"Clin Infect Dis"},{"key":"1649_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.tim.2005.04.005","volume":"13","author":"RR Regoes","year":"2005","unstructured":"Regoes RR, Bonhoeffer S (2005) The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13:269\u2013277","journal-title":"Trends Microbiol"},{"key":"1649_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/096876899294760","volume":"16","author":"TL Hoffman","year":"1999","unstructured":"Hoffman TL, Doms RW (1999) HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol 16:57\u201365","journal-title":"Mol Membr Biol"},{"key":"1649_CR4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1126\/science.1118398","volume":"310","author":"CC Huang","year":"2005","unstructured":"Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL et al (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310:1025\u20131028","journal-title":"Science"},{"key":"1649_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7150\/thno.5392","volume":"3","author":"E Vicenzi","year":"2013","unstructured":"Vicenzi E, Li\u00f2 P, Poli G (2013) The puzzling role of CXCR4 in human immunodeficiency virus infection. Theranostics 3:18\u201325","journal-title":"Theranostics"},{"key":"1649_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7326\/0003-4819-118-9-199305010-00004","volume":"118","author":"M Koot","year":"1993","unstructured":"Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M (1993) Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4\u2009+\u2009cell depletion and progression to AIDS. Ann Intern Med 118:681\u2013688","journal-title":"Ann Intern Med"},{"key":"1649_CR7","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1093\/jac\/dku147","volume":"69","author":"S Raymond","year":"2014","unstructured":"Raymond S, Saliou A, Delobel P, Cazabat M, Pasquier C, Jeanne N, Saun\u00e9 K, Massip P, Marchou B, Izopet J (2014) Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy. J Antimicrob Chemother 69:2527\u20132530","journal-title":"J Antimicrob Chemother"},{"key":"1649_CR8","doi-asserted-by":"publisher","first-page":"e5222","DOI":"10.1097\/MD.0000000000005222","volume":"95","author":"A Castagna","year":"2016","unstructured":"Castagna A, Monno L, Carta S, Galli L, Carrara S, Fedele V, Punzi G, Fanti I, Caramello P, Lepri AC, De Luca A, Ceccherini-Silberstein F, Monforte AD (2016) Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. Medicine 95:e5222","journal-title":"Medicine"},{"key":"1649_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/01.qai.0000152835.17747.47","volume":"38","author":"P Delobel","year":"2015","unstructured":"Delobel P, Sandres-Saun\u00e9 K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J (2015) R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 38:382\u2013392","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1649_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1586\/14787210.2015.1075393","volume":"13","author":"TE Park","year":"2015","unstructured":"Park TE, Mohamed A, Kalabalik J, Sharma R (2015) Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti Infect Ther 13:1195\u20131212","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1649_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/13543784.2017.1378643","volume":"26","author":"H Yingshan","year":"2017","unstructured":"Yingshan H, Mespl\u00e8de T, Wainberg MA (2017) Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opin Investig Drugs 26:1207\u20131213","journal-title":"Expert Opin Investig Drugs"},{"key":"1649_CR12","unstructured":"European AIDS Clinical Society (EACS). EACS Guidelines, Version 9.1. 2018. Available at: \n                    http:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf"},{"key":"1649_CR13","unstructured":"Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (2018) Available at: \n                    https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf"},{"key":"1649_CR14","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1097\/QAD.0b013e32834d0c20","volume":"25","author":"RH Haubrich","year":"2011","unstructured":"Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS 25:2269\u20132278","journal-title":"AIDS"},{"key":"1649_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","volume":"374","author":"JL Lennox","year":"2009","unstructured":"Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS et al (2009) Safety and efficacy of raltegravir based versus efavirenz-based combination therapy in treatment-na\u00efve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374:796\u2013806","journal-title":"Lancet"},{"key":"1649_CR16","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","volume":"79","author":"PE Sax","year":"2012","unstructured":"Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D et al (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 79:2439\u20132448","journal-title":"Lancet"},{"key":"1649_CR17","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"E DeJesus","year":"2012","unstructured":"DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379:2429\u20132438","journal-title":"Lancet"},{"key":"1649_CR18","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"B Clotet","year":"2014","unstructured":"Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S (2014) Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48\u00a0week results from the randomised open-label phase 3b study. Lancet 383:2222\u20132231","journal-title":"Lancet"},{"key":"1649_CR19","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Guti\u00e9rrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G (2013) Dolutegravir plus abacavir lamivudine for the treatment of HIV-1 infection. N Engl J Med 369:1807\u20131818","journal-title":"N Engl J Med"},{"key":"1649_CR20","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1097\/QAD.0b013e3282f12377","volume":"21","author":"JM Murray","year":"2007","unstructured":"Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA (2007) Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21:2315\u20132321","journal-title":"AIDS"},{"key":"1649_CR21","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(01)06802-7","volume":"358","author":"MA Polis","year":"2001","unstructured":"Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, Dimitrov MA, Pizzo P, Yarchoan R, Dimitrov DS (2001) Correlation between reduction in plasma HIV-1 RNA concentration 1\u00a0week after start of antiretroviral treatment and longer-term efficacy. Lancet 358:1760\u20131765","journal-title":"Lancet"},{"key":"1649_CR22","first-page":"448","volume":"15","author":"I Bon","year":"2017","unstructured":"Bon I, Calza L, Musumeci G, Longo S, Bertoldi A, D\u2019Urbano V, Gibellini D, Magistrelli E, Viale PL, Re MC (2017) Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. Curr HIV Res 15:448\u2013455","journal-title":"Curr HIV Res"},{"key":"1649_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/jac\/dkp014","volume":"63","author":"I Malet","year":"2009","unstructured":"Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG (2009) Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 63:795\u2013804","journal-title":"J Antimicrob Chemother"},{"key":"1649_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R et al (2011) In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55:813\u2013821","journal-title":"Antimicrob Agents Chemother"},{"key":"1649_CR25","first-page":"195","volume":"33","author":"V Svicher","year":"2010","unstructured":"Svicher V, D\u2019Arrigo R, Alteri C, Andreoni M, Angarano G, Antinori A et al (2010) Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol 33:195\u2013206","journal-title":"New Microbiol"},{"key":"1649_CR26","first-page":"269","volume":"1","author":"F Tajima","year":"1984","unstructured":"Tajima F, Nei M (1984) Estimation of evolutionary distance between nucleotide sequences. Mol Biol Evol 1:269\u2013285","journal-title":"Mol Biol Evol"},{"key":"1649_CR27","first-page":"418","volume":"3","author":"M Nei","year":"1986","unstructured":"Nei M, Gojobori T (1986) Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3:418\u2013426","journal-title":"Mol Biol Evol"},{"key":"1649_CR28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","volume":"11","author":"LP Vandekerckhove","year":"2011","unstructured":"Vandekerckhove LP, Wensing AM, Kaiser R, Brun-V\u00e9zinet F, Clotet B, De Luca A et al (2011) European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 11:394\u2013407","journal-title":"Lancet Infect Dis"},{"key":"1649_CR29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3851\/IMP1862","volume":"16","author":"V Svicher","year":"2011","unstructured":"Svicher V, Alteri C, Artese A, Zhang JM, Costa G, Mercurio F et al (2011) Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. Antivir Ther 16:1035\u20131045","journal-title":"Antivir Ther"},{"key":"1649_CR30","doi-asserted-by":"publisher","first-page":"e53603","DOI":"10.1371\/journal.pone.0053603","volume":"8","author":"V Svicher","year":"2012","unstructured":"Svicher V, Cento V, Rozera G, Abbate I, Santoro MM, Armenia D et al (2012) The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLoS ONE 8:e53603","journal-title":"PLoS ONE"},{"key":"1649_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/QAD.0000000000000606","volume":"29","author":"T Mespl\u00e8de","year":"2015","unstructured":"Mespl\u00e8de T, Mo\u00efsi D, Oliveira M, Ibanescu I, Ohnona F, Brenner B, Wainberg MA (2015) Dolutegravir inhibits HIV-1 Env evolution in primary human cells. AIDS 29:659\u2013665","journal-title":"AIDS"},{"key":"1649_CR32","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","volume":"13","author":"F Raffi","year":"2013","unstructured":"Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S (2013) Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96\u00a0week results from a randomised, double blind, noninferiority trial. Lancet Infect Dis 13:927\u2013935","journal-title":"Lancet Infect Dis"},{"key":"1649_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF et al (2013) Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week\u00a048 results from the randomised, double-blind, noninferiority SAILING study. Lancet 382:700\u2013708","journal-title":"Lancet"},{"key":"1649_CR34","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/jac\/dkx475","volume":"73","author":"P Gantner","year":"2018","unstructured":"Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Cheneau C, Beck-Wirth G, Faller JP, Mohseni-Zadeh M, Martinot M, Wainberg MA, Fafi-Kremer S (2018) Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. J Antimicrob Chemother 73:1045\u20131053","journal-title":"J Antimicrob Chemother"}],"container-title":["Virus Genes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11262-019-01649-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-019-01649-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-019-01649-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T19:13:39Z","timestamp":1582312419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11262-019-01649-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1649"],"URL":"https:\/\/doi.org\/10.1007\/s11262-019-01649-z","relation":{},"ISSN":["0920-8569","1572-994X"],"issn-type":[{"value":"0920-8569","type":"print"},{"value":"1572-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no competing interests that might be perceived to influence the results and\/or discussion reported in this paper. However, Francesca Ceccherini-Silberstein reports personal fees from Gilead Sciences, Bristol-Myers Squibb, Abbvie, Roche Diagnostics, Janssen-Cilag, Abbott Molecular, ViiV Healthcare; grants and personal fees from Merck Sharp & Dohme; grants from Italian Ministry of Education, University and Research (MIUR). Carlo Federico Perno reports grants from Italian Ministry of Instruction, University and Research (MIUR), and from Aviralia Foundation; personal fees from Gilead Sciences, Abbvie, Roche Diagnostics, Janssen-Cilag, Abbott Molecular, and grants and personal fees from Bristol-Myers Squibb, Merck Sharp & Dohme, and ViiV Healthcare. All other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted on data collected for clinical purposes. All data used in the study were previously anonymized, according to the requirements set by Italian Data Protection Code (leg. decree 196\/2003) and by the General authorizations issued by the Data Protection Authority. Written informed consent for medical procedures\/interventions performed for routine treatment purposes was collected for each patient included in the ARCA database or from other clinical centers involved in the study, in accordance with the ethics standards of the committee on human experimentation and the Helsinki Declaration (1983 revision).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}